CA35309/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1984	3
1985	2
1986	1
1990	1
1991	2
1992	2
1993	1
1995	1
1996	1
2024	0

1

Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.

Howell SB, Kirmani S, McClay EF, Kim S, Braly P, Plaxe S. Howell SB, et al. Semin Oncol. 1991 Feb;18(1 Suppl 3):5-10. Semin Oncol. 1991. PMID: 2003227 Review.

2

Intraperitoneal chemotherapy with melphalan.

Howell SB, Pfeifle CE, Olshen RA. Howell SB, et al. Ann Intern Med. 1984 Jul;101(1):14-8. doi: 10.7326/0003-4819-101-1-14. Ann Intern Med. 1984. PMID: 6732077

3

Enhancement of drug sensitivity of human malignancies by epidermal growth factor.

Kröning R, Jones JA, Hom DK, Chuang CC, Sanga R, Los G, Howell SB, Christen RD. Kröning R, et al. Br J Cancer. 1995 Sep;72(3):615-9. doi: 10.1038/bjc.1995.382. Br J Cancer. 1995. PMID: 7669570 Free PMC article.

4

Totally implantable system for peritoneal access.

Pfeifle CE, Howell SB, Markman M, Lucas WE. Pfeifle CE, et al. J Clin Oncol. 1984 Nov;2(11):1277-80. doi: 10.1200/JCO.1984.2.11.1277. J Clin Oncol. 1984. PMID: 6491705

5

Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide.

Lindnér P, Heath DD, Shalinsky DR, Howell SB, Naredi P, Hafström L. Lindnér P, et al. Surg Oncol. 1993;2(2):105-12. doi: 10.1016/0960-7404(93)90019-u. Surg Oncol. 1993. PMID: 8252198

6

Pharmacokinetic study of intraperitoneal streptozotocin.

Goel R, McClay EF, Kirmani S, Kim S, Braly PF, Plaxe SC, Alcaraz J, Andrews PA, Reichman B, Markman M, et al. Goel R, et al. Clin Invest Med. 1992 Oct;15(5):420-6. Clin Invest Med. 1992. PMID: 1458714

7

Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.

Lindnér P, Heath D, Howell S, Naredi P, Hafström L. Lindnér P, et al. Clin Cancer Res. 1996 Feb;2(2):311-7. Clin Cancer Res. 1996. PMID: 9816174

8

Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.

Markman M, Howell SB, Lucas WE, Pfeifle CE, Green MR. Markman M, et al. J Clin Oncol. 1984 Dec;2(12):1321-6. doi: 10.1200/JCO.1984.2.12.1321. J Clin Oncol. 1984. PMID: 6542584

9

Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.

Isonishi S, Jekunen AP, Hom DK, Eastman A, Edelstein PS, Thiebaut FB, Christen RD, Howell SB. Isonishi S, et al. J Clin Invest. 1992 Oct;90(4):1436-42. doi: 10.1172/JCI116010. J Clin Invest. 1992. PMID: 1401076 Free PMC article.

10

Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy.

Goel R, Andrews PA, Pfeifle CE, Abramson IS, Kirmani S, Howell SB. Goel R, et al. Eur J Cancer. 1990 Jan;26(1):21-7. doi: 10.1016/0277-5379(90)90251-n. Eur J Cancer. 1990. PMID: 2156545

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year